Erratum: HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia

Anne Ørbo, Marit Arnes, Lena Myreng Lyså, Christer Borgfeldt, Bjørn Straume
In: British Journal of Cancer · 2016 · vol. 115(9) , pp. e15 · doi:10.1038/bjc.2016.330 · PMID:27711084 · W2514674116
erratum OA: hybrid CC0
📄 Open PDF Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-10 ⓘ

This erratum corrects a spelling error in the author list of a previously published paper on HE4 as a tissue marker for endometrial hyperplasia therapy response and progestin resistance.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-10 · read from full text ⓘ

This publication is an erratum/corrigendum to a previously published British Journal of Cancer article titled HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia. The paper does not present new scientific data; it states that the authors identified an error in the spelling of one author’s name and apologizes for the mistake, with the author list clarified to include Christer Borgfeldt correctly. No methods, results, or study limitations are discussed beyond the correction notice. This paper is centrally about endometriosis — it is included in the corpus via its title keyword and context of gynecologic pathology, but it does not explicitly discuss endometriosis; it concerns endometrial hyperplasia and progestin resistance.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Correction to: British Journal of Cancer (2016) 115, 725–730. doi:10.1038/bjc.2016.247 Upon publication of the above paper in the British Journal of Cancer, the authors identified an error in the spelling of one of their names. The authors would like to apologise for this mistake. Christer Borgfeldtappears correctly in the author list above.
Full text 736 characters · extracted from oa-pdf · click to expand
HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia Anne Ørbo, Marit Arnes, Lena Myreng Lyså, Christer Borgfeldt and Bjørn Straume Correction to: British Journal of Cancer (2016) 115, 725–730. doi:10.1038/bjc.2016.247 Upon publication of the above paper in the British Journal of Cancer, the authors identified an error in the spelling of one of their names. The authors would like to apologise for this mistake. Christer Borgfeldt appears correctly in the author list above. & 2016 Cancer Research UK. All rights reserved 0007 – 0920/16 CORRIGENDUM British Journal of Cancer (2016) 115, e15 | doi: 10.1038/bjc.2016.330 www.bjcancer.com | DOI:10.1038/bjc.2016.330 1

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-pdf ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (39)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK